The analysis from the physician-led consultancy firm found that for every $100 spent on physician-administered drugs in the outpatient setting, the hospital retained $58, while the drugmaker retained $42.
“This suggests that hospitals are earning more from administering medicines than the manufacturers who created the medicines and is consistent with recent research published by the Moran Company, which found that in the commercial market, hospitals retain 2.4 times their acquisition cost for a basket of 20 brand-name medicines,” the researchers wrote.
Additionally, the report compared how much of the gross profit of physician-administered drugs physician offices retained in comparison to hospital outpatient settings.
The study found that while physician offices and hospital clinics treat a similar number of patients in the commercial market, hospitals received a larger share of the gross profit. In particular, hospitals retained 91 percent of the gross profit margin, compared to physician offices, which retained just 9 percent.
This discrepancy indicates that commercial payers reimburse hospital clinics at a higher rate, researchers said. In addition, the discrepancy may be explained by the fact that hospital clinics are eligible for discounts not offered to physician clinics, including the 340B program.
More articles on pharmacy:
Carcinogen concerns prompt Sandoz to halt global distribution of heartburn drug
DEA raids some West Coast Kaiser Permanente pharmacies
California biotech files for bankruptcy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
